CRDL CRDL

Cardiol Therapeutics Stock Price

1.49
-0.135 (-8.31%)
Upgrade to Real-Time
Afterhours (Closed)
1.49
Volume 130,207
Bid Price 1.25
Ask Price 1.70
News -
Day High 1.73

Low
1.00

52 Week Range

High
4.96

Day Low 1.4816
Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
$30.66
Canadian Level 1 + USA
Monthly Subscription
for only
$38.05
Small Cap Basic
Monthly Subscription
for only
$33.03
VAT not included
Company Name Stock Ticker Symbol Market Type
Cardiol Therapeutics Inc CRDL NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.135 -8.31% 1.49 18:20:43
Open Price Low Price High Price Close Price Prev Close
1.70 1.4816 1.73 1.49 1.625
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
509 130,207 $ 1.55 $ 201,465 - 1.00 - 4.96
Last Trade Time Type Quantity Stock Price Currency
19:24:55 3 $ 1.55 USD

Period:

Draw Mode:

Cardiol Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 92.27M 61.93M 61.93M $ 61.06k $ - - -3.20
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - -

more financials information »

Cardiol Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CRDL Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.291.701.281.47103,8670.2015.5%
1 Month1.291.701.22391.46187,7030.2015.5%
3 Months1.542.081.001.59308,324-0.05-3.25%
6 Months2.002.361.001.70310,474-0.51-25.5%
1 Year2.634.961.002.79521,694-1.14-43.35%
3 Years2.634.961.002.79521,694-1.14-43.35%
5 Years2.634.961.002.79521,694-1.14-43.35%

Cardiol Therapeutics Description

Cardiol Therapeutics' lead product, CardiolRx, is a pharmaceutically produced oral cannabidiol formulation that is currently being evaluated in a Phase II/III multi-national study, the LANCER trial. Cardiol has also received IND authorization from the FDA to conduct clinical studies to evaluate CardiolRx in two orphan drug indications: (i) a Phase II multi-national trial in acute myocarditis; and (ii) a Phase II multicenter open-label pilot study in recurrent pericarditis.


Your Recent History
NASDAQ
CRDL
Cardiol Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.